Caxton Associates LP Nuvation Bio Inc. Transaction History
Caxton Associates LP
- $3.12 Billion
- Q4 2024
A detailed history of Caxton Associates LP transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Caxton Associates LP holds 44,160 shares of NUVB stock, worth $106,425. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,160
Previous 70,401
37.27%
Holding current value
$106,425
Previous $161,000
27.33%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding NUVB
# of Institutions
170Shares Held
157MCall Options Held
4.6KPut Options Held
154K-
Decheng Capital LLC Menlo Park, CA26MShares$62.6 Million12.81% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$39.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.4MShares$37.1 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$31.5 Million47.43% of portfolio
-
Laurion Capital Management LP New York, NY9.87MShares$23.8 Million0.45% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $524M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...